文献速递乳腺癌支持与姑息治疗

乳腺癌骨转移:每3月唑来膦酸对比每月地舒单抗的成本效果分析

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
PubMed 文献 · J Clin Oncol · 2017-10-12

基于CALGB 70604试验结果,采用Markov模型从美国支付方角度评估每月唑来膦酸、每3月唑来膦酸和每月地舒单抗的成本效果。地舒单抗策略平均成本是仿制唑来膦酸每3月方案的九倍,三组质量调整生命年几乎相同,每3月唑来膦酸因成本最低而最优。敏感性分析显示地舒单抗相对每3月唑来膦酸的增量成本每避免一例SRE为162,918至347,655美元。

要点

  • 每3月唑来膦酸在降低SRE风险上比每月地舒单抗更具成本效果。
  • 地舒单抗策略平均成本是仿制唑来膦酸每3月方案的九倍。
  • 三组质量调整生命年几乎相同,每3月唑来膦酸成本最低。

核心结论

  • 每3月唑来膦酸在降低SRE风险方面比每月地舒单抗更具成本效果,是更合理的替代选择。

研究设计与样本

  • 采用Markov模型,从美国支付方角度计算三种治疗每避免一例SRE的成本,并计算质量调整生命年。

主要发现

  • 地舒单抗治疗策略的平均成本是仿制唑来膦酸每3月方案的九倍。
  • 三种治疗组的质量调整生命年几乎相同。
  • 敏感性分析显示,相对每3月唑来膦酸,地舒单抗每避免一例平均SRE的增量成本范围为162,918至347,655美元。

临床怎么用

  • 每3月唑来膦酸是更具成本效果的选项,可作为每月地舒单抗的更合理替代。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, or the necessity for radiation or surgery to bone metastasis cause considerable morbidity, decrements in quality of life, and costs to the health care system. The results of a recent large randomized trial (Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs. We sought to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases. Methods Using a Markov model, costs per SRE avoided were calculated for the three treatments. Sensitivity analyses were performed where denosumab SRE probabilities were assumed to be 50%, 75%, and 90% lower than the ZA SRE probabilities. Quality-adjusted life-years were also calculated. The analysis was from the US payer perspective. Results The mean costs of the denosumab treatment strategy are nine-fold higher than generic ZA every 3 months. Quality-adjusted life-years were virtually identical in all the three treatment arms; hence, the optimal treatment would be ZA every 3 months because it was the least costly treatment. The sensitivity analyses showed that relative to ZA every 3 months, the incremental costs per mean SRE avoided for denosumab ranged from $162,918 to $347,655. Conclusion ZA every 3 months was more CE in reducing the risks of SRE than monthly denosumab. This analysis was one of the first to incorporate the costs of generic ZA and one of the first independent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respectively. ZA every 3 months is the more CE option and more reasonable alternative to monthly denosumab.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shapiro CL, Moriarty JP, Dusetzina S, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017. PMID: 29023215. doi:10.1200/JCO.2017.73.7437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。